Dicerna Pharmaceuticals, Inc. (DRNA): Price and Financial Metrics


Dicerna Pharmaceuticals, Inc. (DRNA): $38.22

0.22 (+0.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DRNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DRNA Stock Price Chart Interactive Chart >

Price chart for DRNA

DRNA Price/Volume Stats

Current price $38.22 52-week high $40.14
Prev. close $38.00 52-week low $19.06
Day low $38.21 Volume 5,568,900
Day high $38.24 Avg. volume 1,344,033
50-day MA $30.08 Dividend yield N/A
200-day MA $28.68 Market Cap 2.99B

Dicerna Pharmaceuticals, Inc. (DRNA) Company Bio


Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. The company was founded in 2006 and is based in Cambridge, Massachusetts.


DRNA Latest News Stream


Event/Time News Detail
Loading, please wait...

DRNA Latest Social Stream


Loading social stream, please wait...

View Full DRNA Social Stream

Latest DRNA News From Around the Web

Below are the latest news stories about Dicerna Pharmaceuticals Inc that investors may wish to consider to help them evaluate DRNA as an investment opportunity.

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

LEXINGTON, Mass., December 28, 2021--Novo Nordisk today announced that the acquisition of Dicerna, announced on 18 November 2021, has been completed.

Yahoo | December 28, 2021

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

LEXINGTON, Mass., December 25, 2021--Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Yahoo | December 25, 2021

MainStay VP Wellington Small Cap Portfolio Buys iShares Russell 2000 Growth ETF, United Natural ...

Investment company MainStay VP Wellington Small Cap Portfolio (Current Portfolio) buys iShares Russell 2000 Growth ETF, United Natural Foods Inc, Mimecast, Insperity Inc, Chesapeake Energy Corp, sells Ollie's Bargain Outlet Holdings Inc, Apellis Pharmaceuticals Inc, Children's Place Inc, Hostess Brands Inc, Boston Beer Co Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, MainStay VP Wellington Small Cap Portfolio.

Yahoo | December 23, 2021

Sumitomo Mitsui Trust Holdings Inc. Trims Stock Position in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)

Sumitomo Mitsui Trust Holdings Inc. lessened its position in shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) by 94.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,901 shares of the biopharmaceutical companys stock after selling 432,596 shares during the quarter. Sumitomo Mitsui Trust Holdings []

Transcript Daily | December 22, 2021

-$0.44 EPS Expected for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) This Quarter

Equities analysts forecast that Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will report earnings of ($0.44) per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Dicerna Pharmaceuticals earnings. The highest EPS estimate is ($0.04) and the lowest is ($0.99). Dicerna Pharmaceuticals reported earnings per share of ($0.49) during the same quarter last []

Transcript Daily | December 16, 2021

Read More 'DRNA' Stories Here

DRNA Price Returns

1-mo N/A
3-mo N/A
6-mo 0.50%
1-year 46.66%
3-year 215.87%
5-year 1,101.89%
YTD N/A
2021 0.00%
2020 0.00%
2019 106.08%
2018 18.38%
2017 213.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8877 seconds.